Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (OTCMKTS:MURGY) Sets New 52-Week High – Should You Buy?

Shares of Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (OTCMKTS:MURGY) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $11.20 and last traded at $11.16, with a volume of 201519 shares traded. The stock had previously closed at $10.98.

Analyst Ratings Changes

MURGY has been the topic of a number of recent analyst reports. Berenberg Bank cut shares of Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 25th. Jefferies Financial Group downgraded shares of Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München from a “buy” rating to a “hold” rating in a report on Monday, October 21st. Finally, UBS Group downgraded Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 19th.

Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München Stock Down 0.7 %

The stock has a market cap of $73.63 billion, a price-to-earnings ratio of 7.16, a P/E/G ratio of 1.73 and a beta of 1.02. The business has a fifty day moving average of $10.41 and a 200 day moving average of $10.36. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.12 and a quick ratio of 1.12.

About Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München

Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München engages in the insurance and reinsurance businesses worldwide. It also offers life and health reinsurance solutions, such as digital underwriting and advanced analytics solutions, health insurance management system, financial market risks, financing, portfolio risk management, digitalized investment-linked solution, MIRA digital suite, MIRA POS, MIRApply insured and physician, claims risk adjustment, CLARA plus, data analytics, underwriting and claims, medical research, capital management, and health market.